In another study, a novel EphA2-targeting antibody-directed nanotherapeutic, encapsulating a labile prodrug of docetaxel (EphA2-ILs-DTXp), was developed to treat EphA2- expressing bladder cancers [120]. The gene discussed is EPHA2; the disease is urinary bladder cancer.